研究者業績
基本情報
- 所属
- 藤田医科大学 感染症研究センター
- 研究者番号
- 71013744
- ORCID ID
https://orcid.org/0000-0001-7111-8012- J-GLOBAL ID
- 202401001157209444
- researchmap会員ID
- R000079950
論文
15-
Antimicrobial Agents and Chemotherapy 2026年4月1日
-
Organic Letters 2026年3月17日
-
Nature communications 13(1) 7575-7575 2022年12月20日The development of new antibacterial drugs with different mechanisms of action is urgently needed to address antimicrobial resistance. MraY is an essential membrane enzyme required for bacterial cell wall synthesis. Sphaerimicins are naturally occurring macrocyclic nucleoside inhibitors of MraY and are considered a promising target in antibacterial discovery. However, developing sphaerimicins as antibacterials has been challenging due to their complex macrocyclic structures. In this study, we construct their characteristic macrocyclic skeleton via two key reactions. Having then determined the structure of a sphaerimicin analogue bound to MraY, we use a structure-guided approach to design simplified sphaerimicin analogues. These analogues retain potency against MraY and exhibit potent antibacterial activity against Gram-positive bacteria, including clinically isolated drug resistant strains of S. aureus and E. faecium. Our study combines synthetic chemistry, structural biology, and microbiology to provide a platform for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.